MedWatch

Despite downgrades and stock decline, Ambu chair maintains trust in leadership

Since spring, Ambu's stock price has more than halved. Neither this nor Tuesday's downgrade has shaken the faith of the board in the medtech company.

Photo: Ida Munch/ERH

Two downgrades in just a few months and a share price that has been more than halved haven't caused any cracks in the relationship between Ambu's leadership and its board, says Chairman of the Board at Ambu Jørgen Jensen. News broke on Tuesday that Ambu has downgraded its guidance as a consequence of shipping delays.

"Ambu's CEO and leadership have my full confidence. We have laid a clear strategic course for Ambu, which we are executing on as planned. Ambu is positioned strongly as the creator of the single-use endoscopes market – a market with a significant potential," says Jensen in a written response to the question of whether there is still trust in the leadership.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs